Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland

Martinez-Barbera JP, Buslei R (2015) Adamantinomatous craniopharyngioma: Pathology, molecular genetics and mouse models. J Pediatr Endocrinol Metab 28(1–2):7–17

CAS  PubMed  Google Scholar 

Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S, Craniopharyngioma (2019) Nat Rev Dis Prim. 5(1)

Müller HL, Merchant TE, Puget S, Martinez-Barbera JP (2017) New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 13(5):299–312. https://doi.org/10.1038/nrendo.2016.217

Article  PubMed  Google Scholar 

Karavitaki N, Cudlip S, Adams CBT, Wass JAH (2006) Craniopharyngiomas Endocr Rev 27(4):371–397

Article  PubMed  Google Scholar 

Boekhoff S, Bison B, Eveslage M, Sowithayasakul P, Müller HL (2019) Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007. Pituitary 22(5):532–541. https://doi.org/10.1007/s11102-019-00983-7

Article  PubMed  Google Scholar 

Ordóñez-Rubiano EG, Forbes JA, Morgenstern PF, Arko L, Dobri GA, Greenfield JP et al (2019) Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas. J Neurosurg 131(4):1163–1171

Article  PubMed  Google Scholar 

Larkin SJ, Ansorge O (2013) Pathology and pathogenesis of craniopharyngiomas. Pituitary 16(1):9–17

Article  PubMed  Google Scholar 

Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrübl F et al (2005) Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109(6):589–597

Article  CAS  PubMed  Google Scholar 

Hölsken A, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R (2010) Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated wnt-signalling. Acta Neuropathol 119(5):631–639

Article  PubMed  Google Scholar 

Martinez-Barbera JP, Andoniadou CL (2016) Concise Review: Paracrine Role of Stem cells in Pituitary tumors: a focus on Adamantinomatous Craniopharyngioma. Stem Cells 34(2):268–276

Article  CAS  PubMed  Google Scholar 

Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Le Tissier P et al (2012) Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 124(2):259–271

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kirkland JL, Tchkonia T, Cellular Senescence A, Translational Perspective (2017) EBioMedicine 21:21–28. https://doi.org/10.1016/j.ebiom.2017.04.013

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Meljem JM, Martinez-Barbera JP (2018) Senescence drives non-cell autonomous tumorigenesis in the pituitary gland. Mol Cell Oncol 5(3):1–3. https://doi.org/10.1080/23723556.2018.1435180

Article  Google Scholar 

Coveñas R, Muñoz M (2014) Cancer progression and substance P. Histol Histopathol 29(7):881–890

PubMed  Google Scholar 

Muñoz MF, Argüelles S, Rosso M, Medina R, Coveñas R, Ayala A et al (2022) The neurokinin-1 receptor is essential for the viability of human glioma cells: a possible target for treating glioblastoma. Biomed Res Int 2022:6291504. https://doi.org/10.1155/2022/6291504

Esteban F, Muñoz M, González-Moles MA, Rosso M (2006) A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25(1):137–145

Article  CAS  PubMed  Google Scholar 

Roth KA, Krause JE (1990) Substance-P is Present in a subset of Thyrotrophs in the human Pituitary*. J Clin Endocrinol Metab 71(5):1089–1095

Article  CAS  PubMed  Google Scholar 

Muñoz M, Coveñas R, Esteban F, Redondo M (2015) The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci 40(2):441–463

Article  PubMed  Google Scholar 

Isorna I, González-Moles MÁ, Muñoz M, Esteban F (2023) Substance P and Neurokinin-1 receptor system in thyroid Cancer: potential targets for New Molecular therapies. J Clin Med 12(19):6409

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE et al (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol 135(5):757–777. https://doi.org/10.1007/s00401-018-1830-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mario Gonzalez-Meljem J, Haston S, Carreno G, Apps JR, Pozzi S, Stache C et al (2017) Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat Commun 8(1):1–14. https://doi.org/10.1038/s41467-017-01992-5

Article  CAS  Google Scholar 

Isorna I, Esteban F, Solanellas J, Coveñas R, Muñoz M (2020) The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. Eur J Histochem 64(2):139–147

Article  Google Scholar 

Mondal M, Mukherjee S, Bhattacharyya D (2014) Contribution of phenylalanine side chain intercalation to the TATA-box binding protein–DNA interaction: molecular dynamics and dispersion-corrected density functional theory studies. J Mol Model 20(11):2499. https://doi.org/10.1210/jcem-71-5-1089

Article  Google Scholar 

Muñoz M, Coveñas R (2020) The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers (Basel) 12(9):1–22

Article  Google Scholar 

Chang MM, Leeman SE, Niall HD (1971) Amino-acid sequence of Substance P. Nat New Biol 232(29):86–87

Article  CAS  PubMed  Google Scholar 

Zhang Y-X, Li X-F, Yuan G-Q, Hu H, Song X-Y, Li J-Y et al (2017) β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition. J Biol Chem 292(21):8933–8947

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28(2):187–193

Article  PubMed  Google Scholar 

Mei G, Xia L, Zhou J, Zhang Y, Tuo Y, Fu S et al (2013) Neuropeptide SP activates the WNT signal transduction pathway and enhances the proliferation of bone marrow stromal stem cells. Cell Biol Int 37(11):1225–1232. https://doi.org/10.1002/cbin.10158

Article  CAS  PubMed  Google Scholar 

Ilmer M, Garnier A, Vykoukal J, Alt E, von Schweinitz D, Kappler R et al (2015) Targeting the Neurokinin-1 receptor compromises canonical wnt signaling in Hepatoblastoma. Mol Cancer Ther 14(12):2712–2721

Article  CAS  PubMed  Google Scholar 

Garnier A, Vykoukal J, Hubertus J, Alt E, Von Schweinitz D, Kappler R et al (2015) Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol 47(1):151–160

Article  CAS  PubMed  Google Scholar 

Lim JE, Chung E, Son Y (2017) A neuropeptide, Substance-P, directly induces tissue-repairing M2 like macrophages by activating the PI3K/Akt/mTOR pathway even in the presence of IFNγ. Sci Rep 7(1):9417

Article  PubMed  PubMed Central  Google Scholar 

Robinson P, Rodriguez E, Muñoz M (2022) Substance P-Friend or foe. J Clin Med 11(13):3609. https://doi.org/10.3390/jcm11133609

Article  PubMed  PubMed Central  Google Scholar 

Guo C-J, Lai J-P, Luo H-M, Douglas SD, Ho W-Z (2002) Substance P up-regulates macrophage inflammatory protein-1β expression in human T lymphocytes. J Neuroimmunol 131(1–2):160–167

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201(2):167–180

留言 (0)

沒有登入
gif